Impact of Rosuvastatin on Risk Markers of Venous Thromboembolism During Systemic Therapy for Advanced Cancer.

Trial Profile

Impact of Rosuvastatin on Risk Markers of Venous Thromboembolism During Systemic Therapy for Advanced Cancer.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Feb 2016

At a glance

  • Drugs Rosuvastatin (Primary)
  • Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
  • Focus Pharmacodynamics
  • Acronyms DISOLVE
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 28 Dec 2015 Planned End Date changed from 1 Sep 15 to 1 Sep 2016 as reported by ClinicalTrials.gov.
    • 28 Dec 2015 Planned primary completion date changed from 1 Jul 2015 to 1 Jul 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top